As I leave Montreal’s WPC 2013, I think back on how I felt leaving Glasgow’s WPC 2010, and the difference is striking. In Glasgow, I was an attendee two years into my Parkinson’s diagnosis, eagerly absorbing as much as I could by attending every session. By Montreal, I was several years into serving as a PDF Research Advocate, as part of the organization’s Parkinson’s Advocates in Research (PAIR) program.
The 3rd World Parkinson Congress includes three days of sessions discussing the latest in Parkinson’s science and care. During day two, PDF reporter and Research Advocate Ronnie Wanetick of Walnut Creek, CA, reported back on two sessions – one covering late stage Parkinson’s and another discussing cognitive symptoms of Parkinson’s.
Excited. Filled with Anticipation. Overwhelmed, in a good way. And to think it all started close to four months ago, in June. That is when my husband John and I decided to attend the World Parkinson’s Congress 2013. Given the fact that it only happens once every three years, it’s the single largest worldwide gathering of all stakeholders in the Parkinson’s field, and we missed it the last go around — we weren’t going to let that happen again.
From Linda Morgan, M.B.A., R.Ph., member People with Parkinson’s Advisory Council I arrived early in Montreal for the 3rd World Parkinson Congress, which will officially start on Tuesday. I came in early to be part of an ‘historic’ dinner and meeting between researchers from the Parkinson Study Group (PSG) and those of us involved with Parkinson’s Advocates in Research (PAIR).
When opening the Sunday Review section of the New York Times this past weekend, I did a double-take as a topic of much discussion here at PDF was featured front and center – trumping commentary on the state of the economy, international relations and the latest political debate. “Do Clinical Trials Work?,” by Clifton Leaf serves as a primer on some of the key issues that prevail within the clinical research enterprise – the tension between scientific inquiry and patient priorities; the odds that study sponsors take when betting on the success of a potential therapy; and the disconnect between those who… Read More
Just a few weeks ago, the Parkinson’s Disease Foundation’s grants review committee – comprising scientists and patient advocates – took on the task of deciding which of the 200 research grant applications we received would be approved for funding. PDF had the resources to fund only 10 worthy projects. Researchers working on innovative, viable projects continually face the challenge of limited available funding. And funders, such as government agencies and foundations like PDF, have to make difficult choices based on available resources. How can PDF meet the challenge to find sufficient funds to support the most promising research in tough economic… Read More